Startup profile for Imagen Technologies: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

Imagen Technologies funding, valuation and investors

Physician-led diagnostic imaging and radiology services supported by proprietary AI and workflow technology.

Verified company research · funding, investors and latest developments

Keep track of Imagen Technologies

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Not publicly disclosed

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

private

growth

Source links not recorded Last verified: 2026-11-21

Overview

Imagen Technologies provides diagnostic imaging services to healthcare organizations through a physician-led radiology practice and supporting technology. Its November 18, 2026 announcement reports more than $100 million in growth capital raised during 2026, without identifying a single exact round, financing composition, valuation or current investors.

Why Imagen Technologies is interesting

The financing disclosure concerns capital raised during 2026, rather than a specifically described $100 million round. Its model combines clinical staffing, imaging services and AI development; access to imaging studies is a training-data right, not evidence that a model is trained, validated or clinically deployed.

Product & use cases

The company describes radiology services for hospitals, health systems and physician groups, alongside a reading platform, worklist routing, AI support and quality-review tools. Its November 2026 announcement says new capital will support radiologist recruitment, retention, clinical resources and technology.

Key facts

  • November 18, 2026 issuer disclosure: more than $100M in growth capital raised during 2026. Exact transactions, instruments, allocations, valuation and legal closing dates are not specified.
  • The issuer says it secured rights to up to 150 million additional imaging studies for AI development; this is access capacity, not a count of studies already used to train a validated model.
  • The company identifies Alex Dresner as co-founder and CEO on its leadership page: https://imagen.ai/about.

Notable stories

Market / IPO context

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.